Concentrations of a new antitumor agent, 1-hexylcarbamoyl-5-fluorouracil in serum and gynecologic tumor tissue.
The concentrations of 1-hexylcarbamoyl-5-fluorouracil (HCFU), were determined in sera and in tissues of patients with gynecologic cancers. In patients who received a single administration of 600 mg of HCFU, the concentrations of 5FU in tissues were higher than 0.05 microgram/g, which has been appreciated as a sufficiently effective concentration to act on cancer cells. The concentration of 5FU in tissues ranged from one-fifth to one-tenth of those in sera. In patients who received daily administrations of 600 mg of HCFU for more than 28 days, the concentrations of 5FU in tissues were about 0.05 microgram/g, while serum concentrations were lower than 0.02 microgram/ml. The concentrations of 5FU in tissues of patients who received daily administrations of 600 mg of HCFU for more than 28 days and a single additional administration of 200 mg of HCFU were the same as those in patients who received a single administration of 600 mg of HCFU immediately before the determinations. In patients who received 400 mg of HCFU per day divided into 4 doses, the concentrations of 5FU in tissue might be higher than 0.05 microgram/g, based on the concentrations in sera. HCFU might be effective against gynecologic cancers when used in maintenance therapy at a lower dosage (300--400 mg) than previously estimated.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000378:metabolism*
D000970:Antineoplastic Agents; C017367:carmofur; D005472:Fluorouracil